Amendments to the Claims:

Please amend claims 26-28. Please add new claims 52-59. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.– 5. (**Canceled**)

6. (**Previously Presented**) The method of claim 26 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

7. (**Canceled**)

8. (**Previously Presented**) The method of claim 26 wherein the reovirus is a mammalian reovirus.

9. (**Original**) The method of claim 8 wherein the mammalian reovirus is a human reovirus.

10. (**Original**) The method of claim 9 wherein the human reovirus is a serotype 3 reovirus.

11. (**Original**) The method of claim 10 wherein the serotype 3 reovirus is a Dearing strain reovirus.

12. – 15. (**Canceled**)

16. **(Previously Presented)** The method of claim 26 wherein the reovirus is administered in multiple doses prior to administration of the chemotherapeutic agent.

17. – 21. **(Canceled)**

22. **(Previously Presented)** The method of claim 26 wherein the reovirus is administered systemically.

23. – 25. **(Canceled)**

26. **(Previously Presented)** A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

(a) identifying a subject including ras-activated neoplastic cells susceptible to a chemotherapeutic agent;

(b) administering to the subject an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and

(c) administering to the subject an effective amount of [[a]]the chemotherapeutic agent,

wherein the infection prevents the ras-activated neoplasm from developing ~~development of~~ drug resistance to the chemotherapeutic agent.

27. **(Currently amended)** A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

~~(a) identifying a subject including ras-activated neoplastic cells susceptible to a chemotherapeutic agent;~~

[[(b)]](a) administering, to a subject having a ras-activated neoplasm capable of developing drug resistance to a chemotherapeutic agent, ~~to the subject~~

an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and

[[(c)]](b) administering to the subject an effective amount of [[a]]the chemotherapeutic agent,

~~wherein the reovirus is administered prior to administration of the chemotherapeutic agent, and~~ wherein the infection prevents the ras-activated neoplasm from developing ~~development of~~ drug resistance to the chemotherapeutic agent.

28. (**Currently amended**) A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

(a) ~~identifying~~ determining, in a subject having a ras-activated neoplasm, if the ras activated neoplasm includes ~~including~~ ras-activated neoplastic cells ~~susceptible~~ that are refractory to a chemotherapeutic agent;

(b) administering to the subject an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and

(c) administering to the subject an effective amount of [[a]]the chemotherapeutic agent,

~~wherein the reovirus and the chemotherapeutic agent are administered concurrently, and~~ wherein the infection prevents the ras-activated neoplasm from developing ~~development of~~ drug resistance to the chemotherapeutic agent.

29. (**Original**) The method of claim 26 wherein the chemotherapeutic agent is cisplatin.

30. **(Previously Presented)** The method of claim 26 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

31. **(Withdrawn)** A method of sensitizing a neoplastic cell to a chemotherapeutic agent, comprising: (a) administering to said neoplastic cell an effective amount of a virus, said virus being capable of selectively infecting neoplastic cells; and (b) administering an effective amount of the chemotherapeutic agent to said cell.

32. **(Withdrawn)** The method of claim 31 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, delNS1 virus, p53-expressing viruses, ONYX-015, Delta24, and vesicular stomatitis virus.

33. **(Withdrawn)** A method of treating a subject with a chemotherapeutic agent wherein said subject harbors a proliferative disorder and neoplastic cells, comprising: (a) administering to the subject an effective amount of a virus under conditions that result in infection of the neoplastic cells by the virus; and (b) administering an effective amount of the chemotherapeutic agent to said subject.

34. **(Withdrawn)** The method of claim 33 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, delNS1 virus, p53-expressing viruses, ONYX-015, Delta24, and vesicular stomatitis virus.

35. **(Previously Presented)** The method of claim 27 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate,

hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

36. **(Previously Presented)** The method of claim 27 wherein the reovirus is a mammalian reovirus.

37. **(Previously Presented)** The method of claim 36 wherein the mammalian reovirus is a human reovirus.

38. **(Previously Presented)** The method of claim 37 wherein the human reovirus is a serotype 3 reovirus.

39. **(Previously Presented)** The method of claim 38 wherein the serotype 3 reovirus is a Dearing strain reovirus.

40. **(Previously Presented)** The method of claim 27 wherein the reovirus is administered in multiple doses prior to administration of the chemotherapeutic agent.

41. **(Previously Presented)** The method of claim 27 wherein the reovirus is administered systemically.

42. **(Previously Presented)** The method of claim 27 wherein the chemotherapeutic agent is cisplatin.

43. **(Previously Presented)** The method of claim 27 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

44. **(Previously Presented)** The method of claim 28 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

45. **(Previously Presented)** The method of claim 28 wherein the reovirus is a mammalian reovirus.

46. **(Previously Presented)** The method of claim 45 wherein the mammalian reovirus is a human reovirus.

47. **(Previously Presented)** The method of claim 46 wherein the human reovirus is a serotype 3 reovirus.

48. **(Previously Presented)** The method of claim 47 wherein the serotype 3 reovirus is a Dearing strain reovirus.

49. **(Previously Presented)** The method of claim 28 wherein the reovirus is administered systemically.

50. **(Previously Presented)** The method of claim 28 wherein the chemotherapeutic agent is cisplatin.

51. **(Previously Presented)** The method of claim 28 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

52. (**New**) The method of claim 26, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.

53. (**New**) The method of claim 26, wherein the reovirus and the chemotherapeutic agent are administered concurrently.

54. (**New**) The method of claim 27, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.

55. (**New**) The method of claim 27, wherein the reovirus and the chemotherapeutic agent are administered concurrently.

56. (**New**) The method of claim 28, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.

57. (**New**) The method of claim 28, wherein the reovirus and the chemotherapeutic agent are administered concurrently.

58. (**New**) The method of claim 26, wherein the ras activated neoplasm comprises ras-activated neoplastic cells that are refractory to the chemotherapeutic agent.

59. (**New**) The method of claim 27, wherein the ras activated neoplasm comprises ras-activated neoplastic cells that are refractory to the chemotherapeutic agent.